Related Experiment Videos
Abstract:
Although ifosfamide first underwent clinical trials 15 years ago, it has largely been ignored by the American oncology community until the last few years. Earlier concerns about dose-limiting hemorrhagic cystitis have been mitigated by the development of effective urothelial protectors such as mesna. Furthermore, ifosfamide is not completely cross-resistant with cyclophosphamide. Ifosfamide has activity in a variety of disseminated refractory solid tumors that do not traditionally respond to conventional alkylating agent therapy, specifically refractory germ cell tumors, soft tissue sarcomas, and malignant lymphomas. The decreased myelosuppression and lack of apparent cross-resistance compared with cyclophosphamide make ifosfamide an ideal drug for inclusion in combination chemotherapy. While clarification of the differences between ifosfamide and cyclophosphamide is ongoing, ifosfamide may eventually replace cyclophosphamide in conventional combination chemotherapy regimens for a variety of solid tumors. At present, it has clear-cut major activity in refractory germ cell tumors and has become an integral component of a curative salvage regimen.
Insights
Ifosfamide, an alkylating agent, shows significant efficacy in refractory solid tumors like germ cell tumors and sarcomas. Its use is expanding due to reduced side effects and lack of cross-resistance with cyclophosphamide.
Area of Science:
- Oncology
- Pharmacology
Background:
- Ifosfamide has been underutilized in American oncology despite earlier clinical trials.
- Concerns regarding hemorrhagic cystitis have been addressed by urothelial protectors like mesna.
- Ifosfamide exhibits distinct activity compared to cyclophosphamide, with no complete cross-resistance.
Purpose of the Study:
- To highlight the clinical significance and expanding role of ifosfamide in cancer treatment.
- To emphasize ifosfamide's efficacy in refractory solid tumors.
- To discuss ifosfamide's advantages over cyclophosphamide in combination chemotherapy.
Main Methods:
- Review of clinical trials and therapeutic applications of ifosfamide.
- Comparison of ifosfamide's efficacy and toxicity profile with cyclophosphamide.
- Analysis of ifosfamide's role in treating specific refractory solid tumors.
Main Results:
- Ifosfamide demonstrates significant activity in refractory germ cell tumors, soft tissue sarcomas, and malignant lymphomas.
- Reduced myelosuppression and lack of cross-resistance make ifosfamide a valuable chemotherapeutic agent.
- Ifosfamide is a key component in salvage regimens for refractory germ cell tumors.
Conclusions:
- Ifosfamide is an effective agent for various refractory solid tumors, particularly germ cell tumors.
- Mitigation of side effects and distinct efficacy suggest ifosfamide may replace cyclophosphamide in some regimens.
- Ifosfamide is integral to curative salvage therapy for refractory germ cell tumors.